drugset

drugset / Trial / NCT06553365

Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors

NCT06553365 ↗

Phase 2 Recruiting 30 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of FCN-159 in patients with specific NF2-associated nerve sheath tumors.

Timeline

Start: 2024-08-15
Primary completion: 2026-07-31
Completion: 2026-07-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Luvometinib	Small molecule	8 mg	Oral

Indications